QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 coeptis-therapeutics-adds-autoimmune-indications-to-exclusive-license-agreement-with-university-of-pittsburgh-for-snap-car-t-and-snap-car-nk

Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to...

 collective-audience-and-3-other-stocks-under-1-insiders-are-buying

The Dow Jones index closed lower by around 100 points on Wednesday. When insiders purchase or sell shares, it indicates their c...

 coeptis-therapeutics-sets-sights-on-expanding-cancer-and-autoimmune-treatments-in-2024

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company dev...

 coeptis-therapeutics-announces-research-demonstrating-the-potential-of-snap-car-t-cells-to-reduce-tumor-burden-and-growth-in-her2-and-cd20-expressing-cancers-will-be-presented-at-sitc-2023

 Poster presentation describes the development of SNAP CAR platform technology as a "universal" CAR therapy with the po...

 coeptis-therapeutics-has-expanded-its-exclusive-license-agreement-with-the-university-of-pittsburgh-to-include-the-snap-car-technology-platform-in-natural-killer-cells

This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Ce...

 ladenburg-thalmann-initiates-coverage-on-coeptis-therapeutics-with-buy-rating-announces-price-target-of-3

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Coeptis Therapeutics (NASDAQ:COEP) with a Buy rating and ann...

 coeptis-therapeutics-phase-1-trials-of-dvx201-for-relapsedrefractory-acute-myeloid-leukemia-or-high-risk-myelodysplastic-syndrome-and-hospitalized-covid-19-patients-showed-no-dose-limiting-toxicities-cytokine-release-syndrome-or-infusion-toxicities

Coeptis Expects To Report Topline Safety And Efficacy Data From The Full Patient Population In Q1 Of 2024

 biorestorative-therapies-and-3-other-stocks-under-3-insiders-are-buying

The Dow Jones closed lower by over 150 points on Thursday. When insiders purchase or sell shares, it indicates their confidence...